Source:http://linkedlifedata.com/resource/pubmed/id/15803357
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2005-4-1
|
pubmed:abstractText |
Interleukin-10 (IL-10) is an immunosuppressive cytokine which may facilitate development of cancer by supporting tumor escape from the immune response. A [TCATA] haplotype formed by polymorphisms at positions -3575, -2763, -1082, -819 and -592 in the promoter of the IL-10 gene is a strong determinant for IL-10 expression. The presence of this haplotype can be determined by analysis of the -592C > A polymorphism. Aim of the present study was to analyze the role of the IL-10 [TCATA] haplotype for breast cancer. We performed a case-control study including 500 female patients with histologically confirmed breast cancer and 500 female, age-matched, healthy control subjects from population-based screening studies. The -592C > A polymorphism was determined by a 5'-nuclease assay (TaqMan). Frequency of the homozygous -592 AA genotype, indicating homozygosity for the [TCATA] haplotype, was 4.2% among patients and 7.3% among controls (p=0.038; odds ratio 0.56; 95% confidence interval 0.32-0.97). IL-10 genotypes were not associated with tumor size, histological grading, estrogen or progesterone receptor status and age at diagnosis. Therefore we conclude that the IL-10 -592C > A promoter polymorphism may be associated with a reduced breast cancer risk.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0167-6806
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
90
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
113-5
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:15803357-Austria,
pubmed-meshheading:15803357-Breast Neoplasms,
pubmed-meshheading:15803357-Case-Control Studies,
pubmed-meshheading:15803357-Female,
pubmed-meshheading:15803357-Genetic Predisposition to Disease,
pubmed-meshheading:15803357-Haplotypes,
pubmed-meshheading:15803357-Humans,
pubmed-meshheading:15803357-Interleukin-10,
pubmed-meshheading:15803357-Matched-Pair Analysis,
pubmed-meshheading:15803357-Polymorphism, Genetic,
pubmed-meshheading:15803357-Promoter Regions, Genetic,
pubmed-meshheading:15803357-Risk
|
pubmed:year |
2005
|
pubmed:articleTitle |
Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk.
|
pubmed:affiliation |
Department of Internal Medicine, Division of Oncology, Medical University Graz, Auenbruggerplatz 15, 8036, Graz, Austria. uwe.langsenlehner@klinikum.graz.at
|
pubmed:publicationType |
Journal Article
|